This activity is supported by an independent education grant from Genmab. This online education program has been designed solely for healthcare professionals in the USA. The information in this program is not suitable for any other country.

Join leading expert Dr. Tara Graff for this accredited virtual workshop. Designed around real-world clinical delivery, this interactive workshop examines the practical journey from writing a bispecific antibody prescription to safely administering the first dose in community practice. Through faculty-led case discussions and real-time decision-making exercises, participants will explore the implementation of standardized step-up dosing protocols, treatment initiation planning, premedication regimens, mandatory hospitalization/observation considerations, patient/caregiver readiness evaluations, and the operational workflows required to support safe outpatient administration.

This workshop is part of a series. Register for workshops 1, 3 and 4 below:

Workshop 1 - Selecting the Right Patient at the Right Time

Workshop 3 - Managing CRS, ICANS, and Infectious Complications

Workshop 4 - Building a Bispecific-Ready Practice

Session Highlights

• Implement standardized step-up dosing protocols and product-specific premedication schedules across intravenous and subcutaneous bispecific antibody therapies.
• Evaluate patient and caregiver readiness using practical operational checklists (e.g., proximity to care facilities, monitoring equipment, social determinants of health).
• Design robust outpatient administration workflows that integrate same-day infusion monitoring and defined care transitions.
• Navigate practical pharmacy and financial logistics, including prior authorizations and required stocking of supportive medications like tocilizumab.
• Analyze interactive clinical scenarios to solve real-world operational bottlenecks encountered during outpatient treatment initiation.

Who Should Attend

This program is designed for:

• Community oncologists
• Community hematologists and hematology-oncologists
• Advanced practice providers (APPs)
• Nurse practitioners
• Oncology nurses
• Pharmacists
• Multidisciplinary care team members involved in treatment delivery and monitoring

Faculty

Tara Graff, DO, MS – Director of Clinical Research at Mission Cancer and Blood in Des Moines, Iowa, playing a integral role in developing the joint clinical trial program with the University of Iowa. Dr Graff primarily focuses on patients with CLL and NHL. She serves on the National Lymphoma Advisory Boards, NHL Advisory Council, LBCL Steering Committee, CIBMTR Lymphoma Working Committee, and works with the Lymphoma Research Foundation. She partners with the Leukemia & Lymphoma Society (now Blood Cancer United) to expand education for rural cancer patients and to train community oncologists on CAR-T and bispecific therapies.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Tara Graff, DO, MS, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for AbbVie, Adaptive Biotechnologies (not active), AstraZeneca, BeOne, BMS, Genmab, Incyte, and Lilly; Consultant for AbbVie, ADC Therapeutics, AstraZeneca, BeOne, BMS, Genentech, Genmab, Gilead/Kite, Janssen, and Pfizer; Speaker for AbbVie, BeOne, and Genmab; Steering Committee for AbbVie and Genmab.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 3, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-345-L01-P

Type of Activity: Application

Fee information

There is no fee for this educational activity.